CA-SIRIUS-THERAPEUTICS
2.2.2024 05:01:26 CET | Business Wire | Press release
Sirius Therapeutics, announced it has dosed the first subject in a Phase 1, first-in-human clinical trial in Australia of SRSD107 on January 30th 2024, its next generation siRNA therapeutic targeting coagulation Factor XI (FXI), for the prevention and treatment of thromboembolic disorders. SRSD107 is the second clinical candidate in the company’s portfolio of next generation siRNA therapeutics to treat cardiovascular diseases. The company recently began clinical trials of SRSD101 in China for the treatment of dyslipidemia following IND clearance from the China National Medical Products Administration.
“This trial is based on in vivo studies that demonstrated a nearly 100% reduction of FXI levels for up to 6 months, without bleeding events, after a single subcutaneous dose,” said Dr. Qunsheng Ji, Sirius Therapeutics’ Chief Executive Officer. “The trial will provide an opportunity to evaluate SRSD107’s potential as a differentiated therapeutic for these common disorders globally.”
The SRSD107 Phase 1 study, which is being conducted in healthy volunteers in Australia, will evaluate SRSD107’s safety, tolerability, pharmacokinetics, and pharmacodynamics at single ascending doses and multiple ascending doses.
About Thromboembolic Disorders
Thrombosis, or blood clot formation, is the common underlying mechanism of most cases of myocardial infarction, ischemic stroke, and venous thromboembolism. According to a study in The Lancet of regional and global mortality, thromboembolic disorders are estimated to cause 1 in 4 deaths worldwide1.
About SRSD107
SRSD107 is a novel double-stranded small interfering ribonucleic acid (siRNA). Developed by Sirius Therapeutics, SRSD107 specifically targets coagulation factor XI (FXI) mRNA and inhibits FXI protein expression, thereby blocking the intrinsic coagulation pathway and promoting anticoagulant/anti-thrombotic effects. SRSD107 has been engineered for the potential to enable once or twice-a-year dosing.
About Sirius Therapeutics
Sirius is an innovative, clinical stage biotech company developing next generation siRNA therapy for global markets. We are dedicated to discovering and developing new treatment options for cardiovascular disease patients. Our most advanced products are SRSD107 for the treatment of thromboembolic disorders, and SRSD101 for the treatment of dyslipidemia. Founded in 2021 by a world-class leadership team and investors, Sirius has established an innovative discovery center in the United States and translational medicine center in China. Sirius has raised nearly US$100 million funding to date from OrbiMed, Creacion Ventures, Hankang Capital, Delos Capital, and the leadership team.
[1] Lozano R, Naghavi M, Foreman K, et al. Lancet. 2012;380, 2095-1128.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240201912539/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Notice of Multi-Color First Quarter 2026 Financial Results Conference Call4.6.2026 05:56:00 CEST | Press release
Multi-Color Corporation (“MCC”) First Quarter 2026 Financial Results Conference Call covering MCC’s performance for the quarter ending March 31, 2026. When: Monday, June 8th at 10:00 A.M. EDT Leaders: Hassan Rmaile, President & CEO and Kathleen Phelps, CFO Access: Existing and prospective investors can gain access to the investor data site (“Data Site”) by following the instructions section 2 below. If you previously had access to the investor data site then no action is needed as your access remains in place. Please submit access requests to the email address listed below in section 2 by 5pm ET Friday, June 5th. The live link to the first quarter 2026 financial results call will be posted to the investor data site. Investor Data Site Access Instructions: 1. Data site access Common Unit, Preferred Unit and Warrant holders of Labels Buyer, LLC (“Company”), holders of notes issued by Multi-Color Corporation and MCC Manufacturing, Inc. (collectively, the “Issuers”) and prospective investo
Kyrgyzstan’s National Interbank Processing Center Partners With Alipay+ to Launch International QR Payments4.6.2026 04:00:00 CEST | Press release
With the support of the National Bank of Kyrgyz Republic, Interbank Processing Center (IPC), Kyrgyzstan’s national payment system operator, and Alipay+, Ant International’s unified wallet gateway, have launched international QR payments for users of the ELCARD Mobile app. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260603760762/en/ (L-R) Altymysh Turatbekov, Chairman of the National Interbank Processing Center; Pan Yan, Head of Strategic Partnership for Alipay+, Ant International The launch was officiated by the Chairman of the National Bank of the Kyrgyz Republic. Almaz Baketaev, Chairman of the National Bank of the Kyrgyz Republic, said: “Our colleagues from IPC together with Alipay+ launched this project last year, and today we are bringing it into practice. Our citizens now have access to a payment system covering merchants worldwide. Wherever they are, they can make payments in any currency easily and without any com
Murata Introduces World’s First 2.2μF/100Vdc Soft-Termination Chip MLCC in 0805-inch Size for Automotive Applications4.6.2026 04:00:00 CEST | Press release
Murata Manufacturing Co., Ltd. (TOKYO: 6981) (ISIN: JP3914400001) introduces the GCJ21BD72A225KE02, a soft-termination chip multilayer ceramic capacitor (MLCC) for automotive powertrain and safety equipment. This world's first soft-termination chip MLCC product achieves the highest available capacitance of 2.2μF at 100Vdc in the smallest 0805-inch (2.0×1.25mm) size*. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260603192945/en/ [Murata Manufacturing Co., Ltd.] 2.2µF/100Vdc Soft-Termination Chip MLCC in 0805-inch Size for Automotive Applications As vehicle electrification accelerates and autonomous driving (AD) and advanced driver-assistance systems (ADAS) grow more sophisticated, engineers face increasing pressure to pack more functionality into tighter board spaces. The wider adoption of 48V power systems further demands components that combine high capacitance, high voltage tolerance, and a small footprint. At the same t
Megaport Launches Storage, Unifying Its Automated Infrastructure Platform Alongside Compute and Network Offerings4.6.2026 00:47:00 CEST | Press release
Megaport Storage enables enterprises to run data-intensive workloads on dedicated software-defined infrastructure with cloud-like agility and predictable costs. Megaport Limited (ASX: MP1) (“Megaport”), a leading global automated infrastructure platform, today announced the launch of Megaport Storage, expanding its platform to deliver integrated compute, network, and storage services. Megaport Storage integrates high-performance, enterprise cloud storage directly into the Megaport Network and Latitude.sh compute platform, giving enterprises a unified foundation that covers the three key pillars of IT infrastructure: compute, network, and storage. The launch marks a culminating step in Megaport’s evolution, delivering predictable costs, seamless scalability, and direct data access wherever customers operate. “With the launch of Megaport Storage, we’re not just connecting your cloud anymore; we’re providing the foundation for it,” said Michael Reid, CEO of Megaport. “By aligning storage
C.H. Robinson Launches World's First AI Technology That Continually Assesses, Improves and Operates Global Supply Chains3.6.2026 18:00:00 CEST | Press release
The newest innovation for Managed Solutions, the Lean AI Engineer, is the brain of the system As the global leader in Lean AI supply chains, C.H. Robinson has built the first AI technology designed to both operate a shipper’s global supply chain and also continuously assess and improve its performance. Now serving the company’s 4PL Managed Solutions customers, a new Lean AI Engineer works in concert with the Lean AI Planner introduced last year to create one connected system that uniquely enhances a supply chain as it runs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260520874794/en/ The Lean AI Engineer can assess an entire supply chain in 25 to 30 minutes and determine improvements before performance is impacted – compared to supply chain assessments that typically take up to four weeks and look backward at what has happened instead of what should happen. While the Lean AI Engineer delivers intel, the Lean AI Planner ma
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom